gave values for GtACR1 and GtACR2 more than 10 times higher than those for CrChR2 ( fig. S5) (25) .
In cultured rat pyramidal neurons, GtACR2 generated hyperpolarizing currents at E h above -88 mV ( Fig. 4B and fig. S6A ). This value corresponds exactly to E Cl under our conditions (table S2) . This strict selectivity is a second advantage of ACRs over the previously reported Cl --conducting ChR mutants, for which E rev is 25 to 30 mV more positive than E Cl , due to residual cation permeability (14, 15) . The range of potentials at which GtACR2 hyperpolarizes the membrane is therefore wider and extends through the values typical for resting potentials of neurons (Fig. 4B) . In current clamp experiments, GtACR2 allowed precisely controlled optical silencing of spikes at frequencies up to at least 25 Hz (Fig. 4C and fig. S6B ).
To compare the efficiency of GtACR2 with that of slow ChloC in neurons, we measured the rheobase of current ramp-evoked spikes at different light intensities using the same solutions and current injection protocol as in (14) . In GtACR2-expressing neurons, full suppression of spiking was observed at 0.005 mW/mm 2 (Fig. 4D ). The fast ChloC mutant, comparable in its kinetics to GtACR2, could not fully suppress spiking even at 10 mW/mm 2 of light, whereas a relatively higher efficiency of slow ChloC with full suppression at~0.1 mW/mm 2 (the reciprocal of this value is plotted in the Fig. 4D , inset) was achieved only at the expense of a dramatically slower kinetics and the necessity to illuminate for at least 12 s (14) (Fig. 4E) . As GtACR2-driven current reached its maximum within 0.1 s (Fig. 4E ), its intensity dependence at any length of the light pulse above 0.1 s was identical to that shown in Fig. 4A . In contrast, the rise of current generated by slow ChloC was 65 times slower (Fig. 4E) . Taking into account the intensity dependence of the current amplitude measured with light stimuli of different duration (Fig. 4F) , full suppression of spiking by slow ChloC with 0.1-s stimuli would occur at 7 mW/mm 2 , whereas by GtACR2 it would be reached at an intensity about three orders of magnitude lower.
The membrane potential, membrane resistance, and rheobase in the dark were not affected by GtACR2 expression in neurons, and the neuronal morphology of GtACR2-expressing neurons was also normal ( fig. S7 ).
Phylogenetically and functionally, ACRs constitute a distinct family of rhodopsins that are fundamentally different from cation channelrhodopsins (CCRs). As natural anion channels, ACRs provide hyperpolarizing optogenetic tools optimized by evolution for extremely high light sensitivity, absolute anion selectivity, and rapid kinetics. A myotrophic lateral sclerosis (ALS), a fatal adult-onset motor neuron disease characterized by progressive loss of upper and lower motor neurons, and frontotemporal dementia (FTD), a common form of dementia characterized by a gradual deterioration in behavior, personality, and/or language, share a common disease spectrum (1, 2) . Transactivation response element DNA-binding protein 43 (TDP-43, TARDBP), is a heterogeneous nuclear ribonucleoprotein (hnRNP) thought to provide the neuropathological link to establish such a disease spectrum (1, 3) . In sporadic ALS (~97% of all cases) and sporadic FTD (~45% of all cases), TDP-43 clears from the nucleus and forms ubiquitinated, cytoplasmic inclusions, termed TDP-43 proteinopathy (2) . Missense mutations in TDP-43 are also linked to familial ALS, strongly supporting the idea that TDP-43 proteinopathy is central to the pathogenesis of sporadic disease (4, 5) . Numerous genetic mutations associated with familial ALS-FTD-VCP, GRN, OPTN, ATXN2, SQSTM1, UBQLN2, PFN1, TBK1, and especially C9ORF72-result in TDP-43 proteinopathy, suggesting a convergent mechanism of neurodegeneration (6-9). Indeed, Tdp-43 is a tightly autoregulated (10), essential gene (11) (12) (13) that is required for neuronal physiology in mice (14) , fruit flies (15) , and zebrafish (16) .
TDP-43's consensus binding motif has been identified as the "UG" dinucleotide repeat (17) . Using a high-throughput sequencing approach combined with cross-linking immunoprecipitation (HITS-CLIP), direct targets of Tdp-43 have been identified (18, 19) . Tdp-43 regulates alternative splicing of a subset of conserved exons by binding to UG-rich domains within proximal intronic regions (18, 19) . However, the majority of Tdp-43 binds to repetitive elements within distal introns, locations where Tdp-43 has no clear function. To explore the RNA splicing role of Tdp-43, we assessed the transcriptome of cells lacking Tdp-43 with RNA-sequencing (RNAseq) (12) . These Cre ER -inducible Tdp-43 knockout mouse embryonic stem (mES) cells (iTDPKO) permit genetic deletion of Tdp-43 within 2 to 3 days of 4-hydroxytamoxifen (4HT) treatment. However, previous sequencing technologies were unable to provide robust transcriptome-wide splicing data. RNA-seq analyses performed on data with greater read length and coverage improved the splicing resolution and allowed us to identify cryptic exons in mES cells lacking Tdp-43 (Fig. 1) .
These splicing variants have not been previously documented in any public databases and strictly appear in nonconserved regions of the genome. Traces of cryptic exons, however, can be detected from previously published RNAseq data ( fig. S1 ). Most cryptic exons introduce frameshifts and/or premature stop codons, characteristic of nonsense-mediated decay (NMD) (table S1). Additionally, we identified a subset of nonstandard cryptic exons that could be categorized as alternative transcriptional start sites, premature polyadenylation sites, or expansions of conserved canonical exons (Fig. 1,  C to E) .
SCIENCE sciencemag.org To determine whether these cryptic exons were direct targets of Tdp-43 binding or missplicing events caused by indirect downstream effects, we looked for evidence of protein-RNA association. Tdp-43 has a very high affinity for UG repeats, with a dissociation constant (K d ) of 14 nM for only six repeats (20) . As predicted, long UG dinucleotide repeats are adjacent to each cryptic exon (Fig. 1F) . Tdp-43 localized to these flanking repeats could potentially act as a general splicing repressor. Further evidence of Tdp-43's role in repressing cryptic exons comes from previous HITS-CLIP data that mapped Tdp-43's direct RNA targets (19) . As expected, clusters of HITS-CLIP reads were mapped onto cryptic exons, further supporting the hypothesis that Tdp-43 represses cryptic exons via direct interaction ( fig. S2) .
We next wanted to establish whether these cryptic exons were a main contributor to the cell death observed after genetic deletion of Tdp-43 (12) . To this end, we designed a fusion protein by coupling TDP-43's N-terminal fragment (N-TDP) to a well-characterized splicing repressor domain, replacing TDP-43's C-terminal fragment (C-TDP) ( Fig. 2A) . N-TDP contains a dimerization domain, nuclear localization signal, and two UG binding RNA recognition motifs but is insufficient to act as a splicing repressor (21) (22) (23) . In contrast, C-TDP is a glycine rich, prion-like domain that harbors the vast majority of mutations associated with ALS and mediates the protein-protein interactions important for splicing (24) . We replaced the C-TDP in our fusion protein with the minimal splicing repressor domain derived from ribonucleoprotein, PTB-binding 1 (RAVER1) (25, 26) . This chimeric protein, termed GTR, translocated to the nucleus, bound to UG repeats, and repressed nearby exons (Fig. 2) .
The GTR construct and associated controls were then transiently transfected into 4HT-treated iTDPKO cells and screened for survivors by means of flow cytometry ( fig. S3) . After exposure to 4HT, the majority of Tdp-43-depleted iTDPKO cells underwent apoptosis. Whereas 4HT-treated iTDPKO cells transfected with control constructs also failed to survive, a portion of those transfected with the GTR construct remained viable.
To rule out the possibility that this rescue was only a transient effect of the GTR expression, we generated a stable transfected line of Tdp-43-deficient cells expressing GTR, termed GTR1 (Fig. 2B) . The growth rate of GTR1 cells was almost identical to iTDPKO cells ( fig. S4) , and the majority of up-regulated and down-regulated transcripts in Tdp-43 knockout cells were also restored to normal values in GTR1 cells (Fig. 2G) , including several transcripts markedly downregulated because of nonsense-mediated decay (table S1). To verify that the rescue effect was correlated with repression of cryptic exons, we RNA-sequenced the GTR1 cells. Indeed, the majority of cryptic exons were highly repressed (Fig. 2, C to E, and table S2) , with the remaining cryptic exons experiencing varying degrees of partial repression (Fig. 2F) . Thus, a deficiency in cryptic exon repression could contribute to cell death.
Because mouse cryptic exons are embedded within nonconserved sequences of the mouse genome, we predicted that human cryptic exons would be located in different regions of the human genome. HeLa cells treated with TDP-43 small interfering RNA (siRNA) (Fig. 3A) expressed numerous cryptic exons (Fig. 3, B to F, and table  S3 ). These human-specific cryptic exons were flanked by UG tandem repeats (Fig. 3G) and were direct targets of TDP-43 ( fig. S5 ). The human cryptic exons shared no overlap with mouse cryptic exons and instead influenced an entirely different set of genes (table S4) .
To further validate this model of cryptic exon repression, we engineered a mini-gene reporter construct encompassing a cryptic exon locus identified in ATG4B and transfected human HeLa cells lacking TDP-43 (Fig. 4) . Under normal conditions, only isoform A was expressed (Fig. 4C, lanes 1, 4, and 7) . After TDP-43 was depleted from the cell, cryptic isoforms B and C were no longer repressed (Fig. 4C, lanes 2,  5, and 8 ). Isoform C was not initially detected through RNA-seq owing to masking by an overlapping cryptic cassette exon; sequencing confirmed its identity as an exon extension ( fig.  S6 ). Isoforms B and C were repressed by GTR ( Fig. 4C, lanes 3, 6, and 9) , supporting the notion that TDP-43 may function as a general repressor whose specificity is determined by its affinity for UG repeats rather than its C-terminal domain.
Having identified a set of cryptic exons that TDP-43 regulates in humans, we then screened postmortem brain tissues from an ALS-FTD cohort (table S5) for the presence of cryptic exons. A reverse transcription polymerase chain reaction (RT-PCR) protocol was designed to amplify across the cryptic exon splice junctions of GPSM2 and ATG4B (Fig. 4D) . Corresponding PCR products were readily observed in all ALS-FTD cases tested but not in controls (Fig. 4E) and validated by  means of DNA sequencing (fig. S7) . Thus, TDP-43 proteinopathy may be correlated with TDP-43 loss of function.
We have found that TDP-43 functions as a splicing repressor of nonconserved cryptic exons ( fig. S8) . A defect in this regulatory mechanism could be linked to TDP-43 proteinopathy in ALS-FTD. Acting as an inhibitory hnRNP, TDP-43 may also regulate conserved exons (18, 19, 27) . Analysis of mouse embryonic stem cell RNA-seq data suggests that some alternatively spliced conserved exons contain UG repeats and may be direct targets of TDP-43 ( fig. S9) . Further work will be required to determine TDP-43's role regarding splicing of conserved exons.
Although the subset of cryptic exons in mice (table S1) is entirely different from that of humans (table S3) , TDP-43's cryptic exon repression function has been maintained across evolution. The protein sequence of TDP-43 is conserved and interchangeable across humans, mice, flies, and nematodes (17, 22) , suggesting that TDP-43 cryptic exon repression could extend beyond mammals as well. From the perspective of human disease, however, we believe that studying genes specifically affected by cryptic exons in the human context could help clarify the development of TDP-43 proteinopathy. Two genes in particular-ATG4B and RANBP1-function in autophagy and nuclear import, respectively. We envision a feedforward loop in which loss of TDP-43 function could undermine the cell's ability to restore TDP-43 to the nucleus, leading to further loss of function ( fig. S10) .
The discovery of TDP-43's role in repressing cryptic exons will advance our understanding of human diseases with TDP-43 proteinopathy and form the basis for previously unidentified biomarkers and therapeutic strategies.
